Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

made this fiscal year one of significant achievement, and we look forward to reporting on additional progress in the coming months."

Recent Operating Highlights

Bavituximab Anti-Cancer Program

Peregrine reported progress in all three Phase II trials in the bavituximab cancer program.

  • Reported updated early results from the first cohort of patients (Stage A) enrolled in a Phase II trial of bavituximab in combination with docetaxel in advanced breast cancer patients. Bavituximab achieved the pre-specified primary endpoint, with 10 of 14 (71%) evaluable patients achieving an objective tumor response according to RECIST criteria.
  • Initiated patient dosing in Stage B of the Phase II trial of bavituximab in combination with docetaxel in advanced breast cancer patients.
  • Completed patient enrollment in Stage A of the Phase II trial of bavituximab in combination with carboplatin and paclitaxel in patients with advanced breast cancer.
  • Completed patient enrollment in Stage A of the Phase II trial of bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer.

Bavituximab Anti-Viral Program

The company continued to advance its bavituximab anti-viral program and received major validation for its anti-PS anti-viral platform.

  • Reported publication of data in Nature Medicine that supports the broad anti-viral potential of Peregrine's anti-PS antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
  • Was awarded a U.S. patent that includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids, including PS, which represent a novel target for anti-viral therapies
    '/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... imaging device developed at Cedars-Sinai can provide early ... brain and are a classic sign of Alzheimer,s ... a clinical trial in Australia. , The researchers ... oral presentation at the Alzheimer,s Association International Conference ... by conference organizers to participate in a "breaking ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... Seattle, Wa (PRWEB) July 13, 2014 ... updated by Vkool.com, this is a comprehensive guide that ... to deal with KP (keratosis pilaris). This ...     Chapter 1: What Is Keratosis Pilaris? ,     Chapter ... Do I Know If I Have KP? , ...
(Date:7/12/2014)... July 12, 2014 The Chicken ... the past five years, buoyed by stable demand for ... management system. “Eggs are a relatively affordable staple for ... egg consumption generally grows in line with the size ... McKitterick. Furthermore, demand for new specialty egg products with ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... acoustic guitars to wounded guitar-playing service members as part of a ... in San Antonio, TX. , ... Pasadena, CA (PRWEB) ... will present over twenty new acoustic guitars to wounded guitar-playing service ...
... siRNA drug delivered systemically, FREMONT, Calif., June ... U.S. Food and Drug Administration (FDA) has,approved the ... drug candidate, DGFi, in kidney transplantation. The Company ... Delayed Graft,Function (DGF) in kidney transplant patients to ...
... at the Silicom Ventures Summit on June 29th-30th in Tel Aviv. ... ... Mind Ltd (SoM) was selected to present its concept and system for ... in Tel Aviv, Israel. The developed system, called SoM-ToUR, is based on ...
... condition a public health priority , , THURSDAY, June 26 ... kidney disease (CKD) is increasing, and the fact it raises ... public health priority, say Taiwanese researchers. , They analyzed data ... part in a standard medical screening program in 1994. The ...
... in the United States in recent years even though the ... by researchers at the Johns Hopkins Bloomberg School of Public ... percent among black men ages 25 to 44 and 12 ... is published in Online First edition of the Journal ...
... June 26 "The only way to flatten ... was the overriding,sentiment at last week,s I3 (insight, ... This statement made by keynote speaker,Wally Gomaa, president ... hospitals and employers must begin (or continue) working,together ...
Cached Medicine News:Health News:Freedom Celebration - Gibson Guitar to Provide Instruments for the Wounded 2Health News:Freedom Celebration - Gibson Guitar to Provide Instruments for the Wounded 3Health News:Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi 2Health News:Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi 3Health News:Step of Mind Ltd Will Present its Concept at the Silicom Ventures Summit 2Health News:Chronic Kidney Disease Growing Globally 2Health News:Researchers study hidden homicide trend 2Health News:Aegis Health Group Revealed Next Generation of Employer-Based Health-Improvement Strategies at Nashville Conference 2
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... schools across the country, teachers are directed to send students ... have a vision issue.  This could be due to the ... the blackboard, poor performance in class or disruptive behavior. The ... difficult and that student could end up in the principal,s ...
... largest professional network for physicians, announced today ... power their medical expert searches. These firms are the ... million in honoraria to physicians last year. Using Doximity,s ... of over 30,000 physician experts. For physicians,  ...
Cached Medicine Technology:Disruptive Students May Not Be Able to See Their Problem 2Disruptive Students May Not Be Able to See Their Problem 3Disruptive Students May Not Be Able to See Their Problem 4Doximity Launches ExpertFinder to Match Clinical Need with Clinical Experts 2
... The PRIMATOM System is a multifunctional ... PRIMUS Linear Accelerator and a SOMATOM ... technology brings image guidance to radiation ... target localization within the treatment room. ...
... SOMATOM Sensation is the highly respected ... coronary branches to visualizing plaque. With its ... industrys fastest rotation time of 0.33s, virtually ... z-Sharp Technology, the system delivers unprecedented diagnostic ...
... The DGH Technology, Inc. Pachmate (DGH 55) ... 6.9 inches long and 3.6 ounces in weight. ... accurate reliable corneal thickness measurements. The Pachmate ... shirt pocket. The Pachmate is rugged in ...
... integrated system that will perform venous occlusion ... You no longer need to manually control ... with and without reactive hyperemia are included. ... for measurements and the frequency with which ...
Medicine Products: